key: cord-0714576-iarp7ccl
authors: Morris, Paraskevi; Lal, Sean; Bao, Shisan; Dennis, Mark; Hunyor, Imre; O’Sullivan, John; Grieve, Stuart M.; Puranik, Rajesh
title: Relationship of Myocardial Gadolinium Enhancement to Late Clinical Outcomes: Implications for the COVID-19 era
date: 2021-11-01
journal: Heart Lung Circ
DOI: 10.1016/j.hlc.2021.08.010
sha: 6f64fe8ae6c1e76cd8a9b1758adb5c24ddf16690
doc_id: 714576
cord_uid: iarp7ccl

nan

Heart, Lung and Circulation (2021) -, --- [2] . To advance understanding regarding implications for prognosis of such findings [2,3], we report late outcomes associated with LGE and preserved LVEF amongst an historical Australian cohort i.e., before the current COVID-19 era. One-hundred-and-fifty-two (152) patients who undertook CMR between January 2008-December 2018 (1.5 Tesla [T]) were retrospectively assessed for attainment of major adverse cardiovascular events (MACE), comprising; cardiovascular (CV)-associated mortality, heart failure (HF) hospitalisation and/or cardiac arrhythmia (atrial fibrillation and/or ventricular fibrillation/tachycardia). LGE1 was defined by a hyper-enhanced myocardial signal, .2SD above normal myocardium. Exclusion criteria included obstructive coronary artery disease (CAD) (defined as .70% stenosis) or current/later developed definite cardiomyopathy phenotype including arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM) or cardiac sarcoidosis. An age/gendermatched control cohort (LGE-) was utilised for comparison. Institutional ethical approval was obtained.

Baseline mean study participant age was 51.9615.3 years (69.7% male). LGE-(n=58) and LGE1 (n=94) groups were well-matched for age (p=0.10) and gender (p=0.35). LGE more frequently occurred with a mid-wall enhancement pattern (n=91) versus transmural (n=4), p,0.0001 ( Figure 1A) Figure 1B ).

In conclusion, LGE on CMR is associated with long-term adverse clinical outcomes. These findings are significant as COVID-19-associated myocarditis incidence is likely to substantially increase, where patients will require careful followup. Uncertainty remains as to whether access to CMR in Australia can meet this clinical demand as there are currently no provisions made for this category of imaging on the Medicare Benefits Schedule. LGE, late gadolinium enhancement; CMR, cardiac magnetic resonance; LVEF, left ventricular ejection fraction.

WHO Coronavirus Disease (COVID-19) Dashboard. Geneva: WHO

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from Coronavirus disease 2019 (COVID-19)

Predictors of mortality in patients with biopsy-proven viral myocarditis: 10-year outcome data